Mark Loeb Professor, Pathology & Molecular Medicine. Contact Information; PHONE: 905-525-9140 ext. 26066; EMAIL: loebm

Mark Loeb. Professor, McMaster University. Verified email at mcmaster.ca - Homepage. Infectious Diseases Pathology and Molecular Medicine. Articles Cited by Public access. Title. Sort. Sort by citations Sort by year Sort by title.

Mark LOEB | Cited by 20,062 | of McMaster University, Hamilton (McMaster) | Read 453 publications | Contact Mark LOEB

Dr. Mark Loeb is a Professor in the Departments of Pathology of Molecular Medicine and Health Research, Evidence, and Impact (formerly Clinical Epidemiology and Biostatistics) at McMaster University where he holds the Michael DeGroote Chair in Infectious Diseases.

2022年11月29日 · Results: In the intention-to-treat analysis, RT-PCR-confirmed COVID-19 occurred in 52 of 497 (10.46%) participants in the medical mask group versus 47 of 507 (9.27%) in the N95 respirator group (hazard ratio [HR], 1.14 [95% CI, 0.77 to 1.69]).

Dr. Mark Loeb, Canada Research Chair in Infectious Diseases, is trying to shed light on these puzzles by studying the prevention of influenza and SARS-CoV-2 (the virus that causes COVID-19).

Mark Loeb's 39 research works with 7,996 citations and 18,833 reads, including: Protocol for a longitudinal cohort study of Lyme disease with physical, mental and immunological assessment

Professor, Department of Pathology and Molecular Medicine, Department of Clinical Epidemiology and Biostatistics, McMaster University. Division Director, Infectious Diseases, McMaster University. Epidemiologic and genomic population-based studies on viral infections including influenza, West Nile, and dengue.

Dr. Loeb has been conducting cluster randomized trials of vaccinating children against influenza in the Hutterite community for the past ten years. He also has been conducting a randomized trial of vitamin D to prevent influenza in children in Vietnam. Dr. Loeb has led three WHO systematic reviews on influenza.

The evidence generated from the trial could be crucial in shaping mpox vaccination strategies to help tackle a large and deadly mpox outbreak escalating in the Democratic Republic of Congo and neighbouring countries. The guidelines are part of a national plan to address the growing drug resistance crisis in Canada.